Jaguar Health (NASDAQ:JAGX) Now Covered by StockNews.com

Research analysts at StockNews.com started coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Jaguar Health Trading Down 6.6 %

JAGX opened at $0.17 on Monday. Jaguar Health has a fifty-two week low of $0.05 and a fifty-two week high of $1.22. The company has a quick ratio of 1.34, a current ratio of 2.00 and a debt-to-equity ratio of 6.33. The company has a fifty day moving average of $0.09 and a two-hundred day moving average of $0.18.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.